The drugs we are developing target abnormal STAT3 pathway regulation, and we are focused on combining our STAT3 compounds with Standard -of- Care chemotherapeutics to form Precision Oncology super-treatments.

Want to see how EurekaConnect can help you and your teams? Fill out the form to talk to us about how we can objectively and measurably improve your organization.